LN-439A, a novel BAP1 inhibitor, suppresses the growth of basal-like breast cancer by degrading KLF5

KIZ OpenIR > 科研部门 > 肿瘤生物学（陈策实）

	LN-439A, a novel BAP1 inhibitor, suppresses the growth of basal-like breast cancer by degrading KLF5
	Wang, TT; Zhang, LL; Li, FB; Zhang, J; Zhang, ZB; Mi, DZ; Sun, J; Zhang, HY; Wang, CY; Chen, YH; Chen, CS
	2024
发表期刊	ACTA PHARMACOLOGICA SINICA
ISSN	1671-4083
摘要	Basal-like breast cancer (BLBC) is the most malignant subtype of breast cancer because of its aggressive clinical behaviour and lack of effective targeted agents. Kr & uuml;ppel-like factor 5 (KLF5) is an oncogenic transcription factor that is highly expressed in BLBC. The deubiquitinase (DUB) BRCA1-associated protein 1 (BAP1) stabilizes KLF5 and promotes BLBC growth and metastasis. Therefore, pharmacological inhibition of the BAP1-KLF5 axis is an effective therapeutic strategy for BLBC. Here, through screening, we identified a series of tetrahydro-beta-carboline derivatives that effectively reduced the protein expression of KLF5 and exhibited strong antitumour activity. Among the investigated compounds, the lead compound LN-439A presented the strongest antitumour activity and inhibitory effect on KLF5 expression. LN-439A suppressed the proliferation and migration of BLBC cells, induced G2/M arrest, and induced apoptosis. Mechanistically, LN-439A functions as a small molecule catalytic inhibitor of BAP1 by binding to the catalytic pocket of BAP1, leading to the ubiquitination and degradation of KLF5. Consistent with this finding, the overexpression of KLF5 suppressed the antitumour effects of LN-439A. In summary, LN-439A is a promising therapeutic agent for BLBC that functions by targeting the BAP1-KLF5 axis.
收录类别	SCI
语种	英语
文献类型	期刊论文
条目标识符	http://ir.kiz.ac.cn/handle/152453/14559
专题	科研部门_肿瘤生物学（陈策实）
推荐引用方式 GB/T 7714	Wang, TT,Zhang, LL,Li, FB,et al. LN-439A, a novel BAP1 inhibitor, suppresses the growth of basal-like breast cancer by degrading KLF5[J]. ACTA PHARMACOLOGICA SINICA,2024.
APA	Wang, TT.,Zhang, LL.,Li, FB.,Zhang, J.,Zhang, ZB.,...&Chen, CS.(2024).LN-439A, a novel BAP1 inhibitor, suppresses the growth of basal-like breast cancer by degrading KLF5.ACTA PHARMACOLOGICA SINICA.
MLA	Wang, TT,et al."LN-439A, a novel BAP1 inhibitor, suppresses the growth of basal-like breast cancer by degrading KLF5".ACTA PHARMACOLOGICA SINICA (2024).

条目包含的文件
文件名称/大小	文献类型	版本类型	开放类型	使用许可
CCS2025040701.pdf（5855KB）	期刊论文	出版稿	开放获取	CC BY-NC-SA	请求全文